These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 23244100)
1. Prediction value of XRCC 1 gene polymorphism on the survival of ovarian cancer treated by adjuvant chemotherapy. Miao J; Zhang X; Tang QL; Wang XY; Kai L Asian Pac J Cancer Prev; 2012; 13(10):5007-10. PubMed ID: 23244100 [TBL] [Abstract][Full Text] [Related]
2. ERCC1, XRCC1, and GSTP1 Polymorphisms and Treatment Outcomes of Advanced Epithelial Ovarian Cancer Patients Treated with Platinum-based Chemotherapy. Liblab S; Vusuratana A; Areepium N Asian Pac J Cancer Prev; 2020 Jul; 21(7):1925-1929. PubMed ID: 32711417 [TBL] [Abstract][Full Text] [Related]
3. Association between polymorphisms of XRCC1 and ADPRT genes and ovarian cancer survival with platinum-based chemotherapy in Chinese population. Li K; Li W Mol Cell Biochem; 2013 Jan; 372(1-2):27-33. PubMed ID: 22983827 [TBL] [Abstract][Full Text] [Related]
4. Role of neoadjuvant chemotherapy in the management of advanced ovarian cancer. Zhao D; Wu LY; Wang XB; Li XG Asian Pac J Cancer Prev; 2015; 16(6):2369-73. PubMed ID: 25824766 [TBL] [Abstract][Full Text] [Related]
5. Association of the Arg194Trp and the Arg399Gln polymorphisms of the XRCC1 gene with risk occurrence and the response to adjuvant therapy among Polish women with breast cancer. Przybylowska-Sygut K; Stanczyk M; Kusinska R; Kordek R; Majsterek I Clin Breast Cancer; 2013 Feb; 13(1):61-8. PubMed ID: 23103366 [TBL] [Abstract][Full Text] [Related]
6. Predictive value of XRCC1 and XRCC3 gene polymorphisms for risk of ovarian cancer death after chemotherapy. Cheng CX; Xue M; Li K; Li WS Asian Pac J Cancer Prev; 2012; 13(6):2541-5. PubMed ID: 22938418 [TBL] [Abstract][Full Text] [Related]
7. BRCA1 expression and improved survival in ovarian cancer patients treated with intraperitoneal cisplatin and paclitaxel: a Gynecologic Oncology Group Study. Lesnock JL; Darcy KM; Tian C; Deloia JA; Thrall MM; Zahn C; Armstrong DK; Birrer MJ; Krivak TC Br J Cancer; 2013 Apr; 108(6):1231-7. PubMed ID: 23462720 [TBL] [Abstract][Full Text] [Related]
8. Second-line Intraperitoneal Platinum-based Therapy Leads to an Increase in Second-line Progression-free Survival for Epithelial Ovarian Cancer. Boisen MM; Lesnock JL; Richard SD; Beriwal S; Kelley JL; Zorn KK; Edwards RP Int J Gynecol Cancer; 2016 May; 26(4):626-31. PubMed ID: 27051048 [TBL] [Abstract][Full Text] [Related]
9. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer. Chang SJ; Bristow RE; Ryu HS Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983 [TBL] [Abstract][Full Text] [Related]
10. Intra-peritoneal cisplatin combined with intravenous paclitaxel in optimally debulked stage 3 ovarian cancer patients: an Izmir Oncology Group study. Unal OU; Yilmaz AU; Yavuzsen T; Akman T; Ellidokuz H Asian Pac J Cancer Prev; 2014; 15(15):6165-9. PubMed ID: 25124592 [TBL] [Abstract][Full Text] [Related]
11. Improved survival trends in platinum-resistant patients with advanced ovarian, fallopian or peritoneal cancer treated with first-line paclitaxel/platinum chemotherapy: the impact of novel agents. Bamias A; Bamia C; Zagouri F; Kostouros E; Kakoyianni K; Rodolakis A; Vlahos G; Haidopoulos D; Thomakos N; Antsaklis A; Dimopoulos MA Oncology; 2013; 84(3):158-65. PubMed ID: 23296063 [TBL] [Abstract][Full Text] [Related]
12. XRCC1 and ADPRT polymorphisms associated with survival in breast cancer cases treated with chemotherapy. Ye S; Rong J; Huang SH; Zheng ZS; Yun M; Wang SM Asian Pac J Cancer Prev; 2012; 13(10):4923-6. PubMed ID: 23244082 [TBL] [Abstract][Full Text] [Related]
13. Kallikrein-related peptidase 10 (KLK10) expression and single nucleotide polymorphisms in ovarian cancer survival. Batra J; Tan OL; O'Mara T; Zammit R; Nagle CM; Clements JA; Kedda MA; Spurdle AB Int J Gynecol Cancer; 2010 May; 20(4):529-36. PubMed ID: 20686372 [TBL] [Abstract][Full Text] [Related]
14. Association between polymorphisms of XRCC1 Arg399Gln and XPD Lys751Gln genes and prognosis of colorectal cancer in a Chinese population. Gan Y; Li XR; Chen DJ; Wu JH Asian Pac J Cancer Prev; 2012; 13(11):5721-4. PubMed ID: 23317245 [TBL] [Abstract][Full Text] [Related]
15. Adenosine triphosphate-based chemotherapy response assay predicts long-term survival of primary epithelial ovarian cancer. Li LY; Kim SW; Nam EJ; Lee J; Kim S; Kim YT Int J Gynecol Cancer; 2019 Feb; 29(2):334-340. PubMed ID: 30718314 [TBL] [Abstract][Full Text] [Related]
16. Multiple Cycles of Neoadjuvant Chemotherapy Associated With Poor Survival in Bulky Stage IIIC and IV Ovarian Cancer. Ren Y; Shi T; Jiang R; Yin S; Wang P; Zang R Int J Gynecol Cancer; 2015 Oct; 25(8):1398-404. PubMed ID: 26222486 [TBL] [Abstract][Full Text] [Related]
17. Outcome of Epithelial Ovarian Cancer: Time for Strategy Trials to Resolve the Problem of Optimal Timing of Surgery. Van de Putte G; Oben J; Prenen L; Schobbens JC; Vlasselaer J; Van Holsbeke C; Debrock G; Van Eycken P; de Jonge E Int J Gynecol Cancer; 2015 Jul; 25(6):993-9. PubMed ID: 25914962 [TBL] [Abstract][Full Text] [Related]
18. DNA repair gene associated with clinical outcome of epithelial ovarian cancer treated with platinum-based chemotherapy. Kang S; Sun HY; Zhou RM; Wang N; Hu P; Li Y Asian Pac J Cancer Prev; 2013; 14(2):941-6. PubMed ID: 23621265 [TBL] [Abstract][Full Text] [Related]
19. Phase II clinical study on the GEMOX regimen as second- line therapy for advanced ovarian cancer. Yuan SF; Zhang LP; Zhu LJ; Chen WJ; Zheng WE; Xiong JP Asian Pac J Cancer Prev; 2013; 14(6):3949-53. PubMed ID: 23886213 [TBL] [Abstract][Full Text] [Related]